This chapter examines the political economy of biopharmaceutical innovation, focusing primarily on vaccines in the Covid-19 pandemic. This analysis aims to make visible the deep entanglements that entrench an extractive and dysfunctional innovation ecosystem, calcifying inequities in global access to essential medicines. The chapter argues that the current inequities in vaccine access are not new or anomalous and that they are the result of a complex yet strategic enmeshment among the logics of war and biomedicine, asset accumulation, and intellectual property. Uneven access to Covid-19 therapeutics can be traced to these three elements, which have built inequity into the political economy of biomedicine long before the current pandemic. Th...
Although IPRs are property rights giving their owners control over assets, they are not guaranteed ...
As biopharmaceutical forms of technology, vaccines constitute one of the most important tools for th...
In a world in which infectious diseases are spreading increasingly faster, the development of new hu...
This chapter examines the political economy of biopharmaceutical innovation, focusing primarily on v...
Through enormous public support and private initiative, biopharmaceutical firms developed safe and e...
In late 2019 and early 2020, a new strain of coronavirus, a family of pathogens causing serious resp...
The response to COVID-19 is indissolubly tied to intellectual property. In an increasingly globalize...
This article examines global vaccine inequity during the COVID-19 pandemic. We critique intellectual...
This paper explores intellectual property and access to essential medicines in the context of the co...
My research project involves an analysis of the compressed upstream supply chain of the Pfizer-BioNT...
This article discusses the medical/therapeutical responses to the COVID-19 pandemic and their politi...
Throughout the COVID-19 pandemic, international access to COVID-19 vaccines and other health technol...
In June 2020, Gilead agreed to provide the USA with 500 000 doses of remdesivir—an antiviral drug wh...
The Declaration on Trade-Related Intellectual Property Rights (TRIPS) and Public Health Agreements w...
The Declaration on Trade-Related Intellectual Property Rights (TRIPS) and Public Health Agreements w...
Although IPRs are property rights giving their owners control over assets, they are not guaranteed ...
As biopharmaceutical forms of technology, vaccines constitute one of the most important tools for th...
In a world in which infectious diseases are spreading increasingly faster, the development of new hu...
This chapter examines the political economy of biopharmaceutical innovation, focusing primarily on v...
Through enormous public support and private initiative, biopharmaceutical firms developed safe and e...
In late 2019 and early 2020, a new strain of coronavirus, a family of pathogens causing serious resp...
The response to COVID-19 is indissolubly tied to intellectual property. In an increasingly globalize...
This article examines global vaccine inequity during the COVID-19 pandemic. We critique intellectual...
This paper explores intellectual property and access to essential medicines in the context of the co...
My research project involves an analysis of the compressed upstream supply chain of the Pfizer-BioNT...
This article discusses the medical/therapeutical responses to the COVID-19 pandemic and their politi...
Throughout the COVID-19 pandemic, international access to COVID-19 vaccines and other health technol...
In June 2020, Gilead agreed to provide the USA with 500 000 doses of remdesivir—an antiviral drug wh...
The Declaration on Trade-Related Intellectual Property Rights (TRIPS) and Public Health Agreements w...
The Declaration on Trade-Related Intellectual Property Rights (TRIPS) and Public Health Agreements w...
Although IPRs are property rights giving their owners control over assets, they are not guaranteed ...
As biopharmaceutical forms of technology, vaccines constitute one of the most important tools for th...
In a world in which infectious diseases are spreading increasingly faster, the development of new hu...